US Pharma MarketingBristol Myers joins Hengrui party in 13-asset deal worth up to $15.2B
Hengrui Pharma has lined up Bristol Myers Squibb as its latest partner in a deal worth up to $15.2 billion. The total value of the pact marks one of the largest East-to-West cross-border deals in industry history. Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next…
It's becoming Hengrui Pharma's world, and some Western drugmakers are just living in it.
China's largest pharma company, which boasts one of the biggest pipelines in the industry, has lined up Bristol Myers Squibb as ...
Source: Endpoints News